2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Tuesday, November 12, 2019

4:30PM-6:00PM: Abstract Number: 2846

Outcomes over the First 5 Years of Follow up in a Very Early Rheumatoid Arthritis (RA) Cohort Recruited over 20 Years: Most of the Improvement Occurred Before the 2011 Implementation of Treat-to-Target (T2T)

5T114: RA – Diagnosis, Manifestations, & Outcomes IV: Outcomes (2846–2851)

4:30PM-6:00PM: Abstract Number: 2845

Pain Patterns in Idiopathic Inflammatory Myopathy (IIM): Associations with Disease Activity Measures (Muscle Enzymes, Manual Muscle Testing 8), Patient-Reported Quality of Life (HAQ) and Pain Scales (Widespread Pain Index (WPI), Symptom Severity Index (SSI) and Visual Analogue Scale)

5T113: Muscle Biology, Myositis & Myopathies II (2840–2845)

4:30PM-6:00PM: Abstract Number: 2842

Paraoxonase 1 Activity Is Abnormal in Patients with Idiopathic Inflammatory Myopathies and Associates with Poor Disease Control

5T113: Muscle Biology, Myositis & Myopathies II (2840–2845)

4:30PM-6:00PM: Abstract Number: 2813

Pentameric, but Not Monomeric C-reactive Protein, Limits the SnRNP-immune Complex Triggered Type I Interferon Response: Implications for Lupus Pathogenesis

5T115: SLE – Etiology & Pathogenesis I: Signaling Pathways (2810–2815)

4:30PM-6:00PM: Abstract Number: 2844

Predictive Factors for Mortality in Anti-melanoma-associated Gene 5 Antibody-associated Interstitial Lung Disease

5T113: Muscle Biology, Myositis & Myopathies II (2840–2845)

4:30PM-6:00PM: Abstract Number: 2823

Progression to Inflammatory Arthritis After Screening Autoantibody Positive in a Non-Clinical Setting

5T109: Epidemiology & Public Health III: RA (2822–2827)

4:30PM-6:00PM: Abstract Number: 2825

Provider Variability in Glucocorticoid Prescribing for Patients with Rheumatoid Arthritis and Impact on Chronic Glucocorticoid Use

5T109: Epidemiology & Public Health III: RA (2822–2827)

4:30PM-6:00PM: Abstract Number: 2849

Radiographic Progression During a 10-Year Follow-Up : Results from the French Cohort ESPOIR

5T114: RA – Diagnosis, Manifestations, & Outcomes IV: Outcomes (2846–2851)

4:30PM-6:00PM: Abstract Number: 2840

Reliability, Validity and Responsiveness of PROMIS PF-20 in Patients with Inflammatory Myopathy

5T113: Muscle Biology, Myositis & Myopathies II (2840–2845)

4:30PM-6:00PM: Abstract Number: 2826

Risk of Serious Infections in Tofacitinib versus Other Biologic Drug Initiators in Patients with Rheumatoid Arthritis: A Multi-database Cohort Study

5T109: Epidemiology & Public Health III: RA (2822–2827)

4:30PM-6:00PM: Abstract Number: 2843

Safety and Efficacy of Lenabasum at Week 68 in an Open-Label Extension of a Phase 2 Study of Lenabasum in Refractory Skin-Predominant Dermatomyositis (DM) Subjects

5T113: Muscle Biology, Myositis & Myopathies II (2840–2845)

4:30PM-6:00PM: Abstract Number: 2848

Semiquantitative Assessment of Synovial Inflammation on US-Guided Synovial Membrane Biopsy Is Contingent to Disease Phase, Autoimmune Profile and Treatment Response in Rheumatoid Arthritis: Large Single Center Experience (SYNGem Cohort)

5T114: RA – Diagnosis, Manifestations, & Outcomes IV: Outcomes (2846–2851)

4:30PM-6:00PM: Abstract Number: 2852

Shared and Differing Risk Factors for PsA, Psoriasis, AS, and RA: A Series of Case-control Studies

5T116: Spondyloarthritis Including Psoriatic Arthritis – Clinical VI: Psoriatic Arthritis Clinical Studies (2852–2857)

4:30PM-6:00PM: Abstract Number: 2833

Shared Decision Making in Routine Clinical Practice: An Assessment of Audio-recorded Consultations with Rheumatoid Arthritis Patients

5T111: Measures of Healthcare Quality II: Quality Improvement in Rheumatology – Still Getting Better (2828–2833)

4:30PM-6:00PM: Abstract Number: 2806

Single Cell RNA-sequencing Reveals Distinct Macrophage Subsets in the Joint with Differing Ontogenies During Steady-state and Arthritis

5T110: Innate Immunity (2804–2809)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].